Compare · ENOV vs STE
ENOV vs STE
Side-by-side comparison of Enovis Corporation (ENOV) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENOV and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $22.62B, about 14.9x ENOV ($1.51B).
- Over the past year, ENOV is down 7.6% and STE is down 2.1% - STE leads by 5.5 points.
- STE has been more active in the news (8 items in the past 4 weeks vs 5 for ENOV).
- ENOV has more recent analyst coverage (20 ratings vs 17 for STE).
- Company
- Enovis Corporation
- STERIS plc (Ireland)
- Price
- $26.34-12.67%
- $231.21-0.53%
- Market cap
- $1.51B
- $22.62B
- 1M return
- +11.54%
- +10.44%
- 1Y return
- -7.63%
- -2.11%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 8
- Recent ratings
- 20
- 17
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest ENOV
- SEC Form 10-Q filed by Enovis Corporation
- Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enovis Announces Second Quarter 2026 Results
- Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
- Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
- BMO Capital Markets initiated coverage on Enovis Corporation with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation
- Director Ortiz Christine was granted 846 shares, increasing direct ownership by 3% to 25,857 units (SEC Form 4)
- SEC Form 11-K filed by Enovis Corporation
- Chief Administrative Officer Engert Oliver bought $20,920 worth of shares (1,000 units at $20.92), increasing direct ownership by 2% to 53,640 units (SEC Form 4)
Latest STE
- SEC Form 8-K filed by STERIS plc (Ireland)
- Amendment: STERIS plc (Ireland) filed SEC Form 8-K: Leadership Update
- STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits
- STERIS Announces Financial Results for Fiscal 2027 First Quarter
- STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
- STERIS Raises Dividend to $0.69 per share
- UBS initiated coverage on Steris with a new price target
- STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
- Director Sohi Mohsen exercised 3,781 units of Ordinary Shares at a strike of $71.40 and covered exercise/tax liability with 1,837 units of Ordinary Shares, increasing direct ownership by 9% to 24,305 units (SEC Form 4)
- SEC Form 11-K filed by STERIS plc (Ireland)